Ginkgo Bioworks Holdings (DNA) Income from Discontinued Operations (2025 - 2026)
Powered by 
Analysis
Ginkgo Bioworks Holdings (DNA) Income from Discontinued Operations (2025 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.12 Bn | 132.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.04 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.63 Bn | 58.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.45 Bn | 52.31 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 40.14 Bn | 35.04 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.29 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.62 Bn | 27.79 Bn | - | - |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | - |
| 10 | Ginkgo Bioworks Holdings | 430.93 Mn | 346.40 Mn | 18.44 Mn | 10.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.61 Mn |
| Mar 31, 2026 | -6.53 Mn |
| Jun 30, 2025 | -7.11 Mn |
| Mar 31, 2025 | -7.65 Mn |